title: Rosiglitazone treatment in nondiabetic subjects with nonalcoholic fatty liver disease.
abstract: BACKGROUND
  Pharmacological treatment options for nonalcoholic fatty liver disease (NAFLD) are limited. It has been suggested that thiazolidinediones may be useful in NAFLD treatment.
  
  
  OBJECTIVE
  An open-label prospective study was conducted to assess the efficacy and safety of rosiglitazone treatment in nondiabetic subjects with NAFLD.
  
  
  METHODS
  A total of 27 subjects (mean age 44 ± 11 years, body mass index 29.2 ± 3.1 kg/m2), with biopsy-confirmed NAFLD and no other complaints, were treated with rosiglitazone 4 mg daily for 6 months.
  
  
  RESULTS
  No adverse events were observed during a 6-month treatment with rosiglitazone. Liver enzymes gradually decreased (alanine transaminase from 101 ± 59 to 58 ± 39 IU/l, aspartate transaminase from 52 ± 24 to 37 ± 15 IU/l; P <0.001). Plasma insulin levels decreased significantly by 30% to 50% in each time point of the oral glucose tolerance test. The homeostatic model assessment index decreased from 3.73 ± 1.89 to 2.06 ± 1.68 (P <0.001). No significant changes in plasma glucose were noted. Plasma adiponectin increased from 2198 ± 1853 to 5734 ± 1999 ng/ml (P <0.001). There were no statistically significant changes in body weight, glycated hemoglobin A1c, plasma lipids, or leptin.
  
  
  CONCLUSIONS
  Rosiglitazone treatment in patients with NAFLD is safe, well-tolerated and leads to a significant improvement in liver function and insulin sensitivity, without adversely affecting the lipid profile.
authors: Department of Internal Medicine and Diabetology, Medical University of Lodz, Łódź, Poland.
authors: Małgorzata
authors: M
authors: Saryusz-Wolska
authors: Elektra
authors: E
authors: Szymańska-Garbacz
authors: Maciej
authors: M
authors: Jabłkowski
authors: Jolanta
authors: J
authors: Białkowska
authors: Maciej
authors: M
authors: Pawłowski
authors: Ewa
authors: E
authors: Kwiecińska
authors: Aleksandra
authors: A
authors: Omulecka
authors: Anna
authors: A
authors: Borkowska
authors: Anna
authors: A
authors: Ignaczak
authors: Jerzy
authors: J
authors: Loba
authors: Leszek
authors: L
authors: Czupryniak
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D005234:Fatty Liver / Q000188:drug therapy; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D065626:Non-alcoholic Fatty Liver Disease; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone